We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+21.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.03B
AUM Growth
+$384M
Cap. Flow
+$76.6M
Cap. Flow %
3.78%
Top 10 Hldgs %
49.69%
Holding
79
New
15
Increased
27
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$71M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$60.3M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$44.3M
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$38.2M
5
INSM icon
Insmed
INSM
+$37.7M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$66.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$35M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$32M
5
PEN icon
Penumbra
PEN
+$31.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Financials 3.41%
3 Miscellaneous 1.69%
4 Communication Services 0.62%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTM
76
DELISTED
NxStage Medical Inc.
NXTM
– –
-657,356
Closed -$16.5M
JUNO
77
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-2,219,616
Closed -$66.3M
SPNC
78
DELISTED
Spectranetics Corp
SPNC
– –
-634,802
Closed -$24.4M
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2017 Portfolio in Review

As of Q3 2017, Redmile Group held 79 positions worth $2.03B, up 23% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group deployed $76.6M of net new capital in Q3 2017, opening 15 new positions and adding to 27 existing holdings. Its largest new stake was AstraZeneca: 1,123,150 shares worth $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Syneos Health, Inc. Class A Common Stock, an estimated $32M trimmed.

  • Redmile Group's largest Q3 2017 buy was AstraZeneca: 1,123,150 shares worth $76.1M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q3 2017, an estimated $60.3M increase.
  • Redmile Group's biggest Q3 2017 reduction was Syneos Health, Inc. Class A Common Stock, cutting an estimated $32M.
  • Redmile Group fully exited Juno Therapeutics, Inc. in Q3 2017, selling an estimated $66.3M.
  • Redmile Group's ten largest holdings make up 50% of its $2.03B portfolio in Q3 2017.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2017.
  • Redmile Group's portfolio value rose 23% quarter-over-quarter to $2.03B.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.